Rochester Medical — Shareholder Meeting (February 2009)
26 slides from Rochester Medical's shareholder meeting presentation, Feb 4, 2009

Slide 1: Rochester Medical Corporation 2009 Annual Meeting
Rochester Medical Corporation 2009 Annual Meeting

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic r

Slide 3: Outline
Outline Corporate Overview Markets Products Financial Highlights Opportunities Potential FemSoft Opportunity Q&A

Slide 4: Company Facts
Company Facts Develop, Manufacture and Sell Disposable Incontinence and Bladder Drainage Devices Three Major Product Categories-Soon to be Four Rochester Medical Brand Sold in Over 75 Countries Focus on North America and Europe Private Label Sales to Major Medical Device Companies 28 Acres, Stewartv

Slide 5: Sales - Brand Focused Growth, Private Label Stability
Sales -Brand Focused Growth Private Label "Stability" F03 F04 F05 F06 F07 F08 RM Branded 6291000 6551000 7351000 10797000 19226000 23848000 Private Label 3081627 2427665 8591000 10834000 13437000 11344000

Slide 6: Market Opportunity - Today
Market Opportunity - Today Products/Markets U.S. U.K. Rest of Europe Total Male External Catheter $50 $18 $60 $128 Intermittent $70 $100 $300 $470 Foley/Urological Catheter $400 $50 $70 $520 TOTALS $520 $168 $430 $1,118 ($ in millions) Extended Care Extended Care AcuteCare

Slide 7: Market Opportunity - Future
Market Opportunity -Future Products/Markets U.S. U.K. Rest of Europe Total Male External Catheter $50 $18 $60 $128 Intermittent $400 $100 $300 $800 Foley/Urological Catheter $400 $50 $70 $520 TOTALS $520 $168 $430 $1,448 ($ in millions) Extended Care Extended Care AcuteCare

Slide 8: Product Superiority: MEC (male external catheters)
Product Superiority MEC (male external catheters) MEC (male external catheters) MEC (male external catheters)

Slide 9: Product Superiority: MEC (male external catheters)
Product Superiority MEC (male external catheters) All Silicone - non-latex Breathable Odorless Proven Quality Largest Global Manufacturer 4 Distinct models Generational Product Improvement in R&D Pipeline

Slide 10: Product Superiority: Intermittent Catheters - Magic3
Product Superiority Intermittent Catheters-Magic3TM Intermittent Catheters-Magic3TM Intermittent Catheters-Magic3TM

Slide 11: Product Superiority: Intermittent Catheters
Product Superiority Intermittent Catheters The only 100% Silicone Intermittent- non-PVC Softness Eyes No leachables No Disposal issues Proprietary Hydrophilic technology The only Intermittent Antibacterial technology The only Silicone / Hydro / Antibacterial combination Major product enhancement jus

Slide 12: Product Superiority: Foley Catheters
Product Superiority Foley Catheters Foley Catheters Foley Catheters

Slide 13: Enhanced Silicone Catheter
Enhanced” sone Catater ee - ™ Pree

Slide 14: Product Superiority: Foley Catheters
Product Superiority Foley Catheters All Silicone - non-latex Patented integrated balloon system Patented drug elution infection control system The only Foley catheter Indicated for infection control The only Foley catheter clinically proven to significantly reduce infection versus silicone control c

Slide 15: Domestic Sales - Rochester Medical Brand
Domestic Sales - Rochester Medical(r) Brand Field Organization Rochester Extensive Provider Distribution Network Effective, well positioned Sales Force Capable, Aggressive and Creative Extended and Acute Care Focus Rochester Medical Brand Only Expect Solid Growth ROCM Homecare Personnel ROCM Sales P

Slide 16: Domestic Sales: Selling MECs, U.S. Private Label
Domestic Sales Selling MECs Valuable, Non-strategic Business Serviced by Centralized Personnel U.S. Private Label Customers

Slide 17: UK Sales Territories
UK Sales Territories Scotland 1 Scotland 2 (part time) North North West South West South North East East Anglia North Thames West Midlands Location of nurses

Slide 18: International Sales
International Sales Selling our MECs and Foleys Private Label Customers

Slide 19: Financials
Financials Sales F2008 $35.2M...68% Branded Annualized Branded Growth 25-30% Q1-09 $8.4 Margin Near 50% 60% Achievable with volume growth Currently pressured by exchange rates Operating Expenses Major investment in sales and marketing infrastructure Fairly flat in the near term Favorable impact from

Slide 20: Opportunities
Opportunities 3 current Major branded growth initiatives UK market (all 3 product lines) Expansion to mainland initiated Hydrosil Discreet (Magic Technology) just introduced US Acute Care market GPO contracts New Reimbursement guidelines Infection Control Focus New Product Enhancements in April 2009

Slide 21: Intermittent Catheter Reimbursement Change
Intermittent Catheter Reimbursement Change- 200/mo. instead of 4/mo. Change is creating opportunity for National DTC approach for incontinence devices-similar to Diabetic Supplies and "Scooter" Ads. DTC campaign has begun but is off to a slower than expected start DTC aproach potentially opens up si

Slide 22: FemSoft
FemSoft(r)

Slide 23: U.S. Theoretical FemSoft Potential
U.S. Theoretical FemSoft Potential 12,000,000 Incontinent Females 5% Penetration = 600,000 Users At Current Reimbursement Assuming 2 devices per day = $937,320,000 Rochester Medical = $468,660,000 Engaged in Preliminary Discussion with Distributors for possible National Campaign * Also working towar

Slide 24: Summary
Summary Excellent Opportunities Rochester Medical in strong position to achieve success Superior, advanced products and technology New market dynamics (reimbursement policies) New focus on infection control Core structure in place Magic Intermittents just introduced worldwide New Enhanced Foley intr

Slide 25: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic r

Slide 26: Rochester Medical Corporation
Rochester Medical Corporation
Source: SEC EDGAR · 8-K filed Feb 4, 2009
More decks from Rochester Medical Corporation
Investor Presentation (August 2013)25 slides · Aug 1, 2013
Investor Presentation (November 2012)25 slides · Nov 27, 2012
Investor Presentation (September 2011)25 slides · Sep 8, 2011
Shareholder Meeting (January 2011)20 slides · Jan 27, 2011
Jefferies 2010 Global Life Sciences Conference39 slides · Jun 10, 2010
Shareholder Meeting (January 2010)39 slides · Jan 29, 2010